ASH 2025 | Epcoritamab for R/R DLBCL: Results from EPCORE NHL-6, by race and ethnicity
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
ASH 2025 | Epcoritamab for R/R DLBCL: Results from EPCORE NHL-6, by race and ethnicity
-
Narrado por:
-
De:
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Adelba Torres, Hospital Auxilio Mutuo, San Juan, PR.
We asked, What does the latest analysis of the EPCORE NHL-6 trial tell us about the efficacy and safety of bispecific antibodies in an ethnically and racially diverse patient population?
In this interview, Torres highlights how the findings from the EPCORE NHL-6 trial support the safe and efficacious administration of subcutaneous epcoritamab in the outpatient setting in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and discusses efficacy and safety findings in an ethnically and racially diverse group of patients.
This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Hosted on Acast. See acast.com/privacy for more information.